Samaxia Showcases Expanded Veterinary Support Portfolio at BVA Live 2026

Samaxia Ltd will be exhibiting at BVA Live 2026 on Stand A25, showcasing an expanded portfolio of non-prescription veterinary products designed to support modern clinical care across dermatology, ophthalmology, nutritional support and infection control.

Visitors to the stand will be able to explore a growing range of digestive, joint, skin and eye care solutions, including Ultradiar Biotic for digestive and microbiome support, Cartimax Capsules for joint and mobility support, and the AGEPI Omega 3 and AGEPI Omega 3 & 6 nutritional support ranges.

The company will also be highlighting additions to its ophthalmology portfolio, including Lacrynet eye cleansing solution, Lacri+ Vitamin A ophthalmic ointment and Lacri+ Eye Drops preservative-free eye care formulations.

Alongside its nutritional and ophthalmology ranges, Samaxia will also be showcasing SANI-99 For Vets, the DEFRA-approved powder-based disinfectant developed to support efficient infection control protocols within veterinary practice whilst reducing storage, transport and plastic waste with an excellent health and safety profile.

Delegates visiting Stand A25 will have the opportunity to take advantage of exclusive BVA Live show offers, live product demonstrations and complimentary product giveaways throughout the exhibition.

Visitors bringing their voucher from the official BVA voucher booklet will be able to collect complimentary samples of LacriProtect, Honeyderm and SANI-99 For Vets, while stocks last.

The stand will also feature live sampling opportunities, including the chance to experience Sensiderm Balm for noses, pads and paws, alongside discussions around practical solutions designed to support the day-to-day realities of veterinary practice.

Delegates will additionally be able to book follow-up meetings with Max Williamson to discuss product trials, practice support and future opportunities following the event.

Visitors to Stand A25 at BVA Live 2026 will also be able to explore the company’s wider dermatology, skin barrier and infection control portfolio.